Pre-Clinical Research
Filter News
Found 6,796 articles
-
Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences
10/17/2019
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data from its oncology pipeline of Red Cell Therapeutics™ at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2019, in Boston, MA,
-
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
10/17/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, continues to further develop antibody candidates that have shown selectivity for the toxic forms of tau.
-
Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/17/2019
Kymera Therapeutics Inc. announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linked to numerous cancers and other diseases.
-
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
10/17/2019
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 26-30, 2019 at the Hynes Convention Center.
-
QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia
10/17/2019
Infigratinib showed improvements in nine measures of bone development in the Fgfr3[Y367C/+] mouse model of achondroplasia at a low dose
-
Navire Pharma, a BridgeBio subsidiary, to Present Data Showing Potential of SHP2 Inhibitor IACS-13909 in Treatment-Resistant Lung Cancer
10/16/2019
Preclinical data shows SHP2 inhibitor enhances activity of osimertinib in EGFR-driven tumor xenografts
-
Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
10/16/2019
The poster presentation is available for download at http://regulusrx.com/publications.
-
Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/16/2019
Sunesis Pharmaceuticals, Inc. announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massachusetts..
-
Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210
10/15/2019
Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical study evaluating THX-210, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide (PEA)
-
Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019
10/15/2019
The FXR agonist TERN-101, currently in Phase 1 studies, demonstrates the potential for liver-enriched tissue distribution
-
Anatara’s gut-targeted dietary supplement completes preclinical testing, demonstrating it can treat inflammatory gastrointestinal disease and may promote mucosal healing
10/14/2019
Successful completion of the preclinical program has provided strong scientific proof that the GaRP dietary supplement has the potential to be game changing
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies
10/10/2019
Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced today that the European and Int'l Shock Societies selected, for an oral presentation, “Pathogen- and damage-associated molecular patterns are immune modified by apoptotic cell adjuvant therapy for acute sepsis in a cecal ligation and puncture mice model, and avoids multi-organ failure and improves survival” to be presented at the XVIIIth Congress of the European Shock Society and IXth Congres
-
Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
10/10/2019
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Company’s Lm technology in mouse tumor models of glioblastoma multiforme (GBM).
-
Evotec and Celmatix enter into strategic collaboration
10/9/2019
The Goal Is To Develop Novel Pre-clinical Programmes For High Unmet Medical Need Conditions For Women
-
MilliporeSigma Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection
10/8/2019
MilliporeSigma introduced its ADC Express TM services for the rapid production of ADCs, which can reduce the time needed to produce development grade constructs for target molecule identification.
-
ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
10/8/2019
ArQule, Inc. announced that it will be presenting research on the company’s pan-AKT inhibitor, miransertib, in a poster presentation at the 2019 ASHG Annual Meeting being held from October 15 to October 19, 2019 in Houston, Texas.
-
Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents
10/7/2019
Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of bioactive factors in milk and the effect of the supplements on brain development in animals.
-
IsoPlexis' New Software & Applications Pave the Way for Novel Functional Understanding of Single-Cell Immune Activation and Further Application Expansion
10/3/2019
IsoPlexis expands visualizations for single-cell mapping and targeting in their new IsoSpeak software suite, as well as new Chip applications on the IsoLight
-
Goldfinch Bio Announces Licensing Agreement with Takeda for CB1 Monoclonal Antibody for the Treatment of Rare and Metabolic Kidney Diseases
10/3/2019
Agreement leverages Goldfinch Bio’s clinical experience and proprietary precision medicine platform in kidney disease